BACKGROUND AND OBJECTIVE: The therapeutic consequences of using the Framingham function calibrated by the REGICOR and Framingham investigators (Framingham-REGICOR) in the Spanish population are unknown. The objective of this study was to determine the differences in the classification of the population coronary risk when using the classical Framingham function (Framingham-Wilson) and that calibrated, and its consequences on the theoretical indication of lipid-lowering treatment. PATIENTS AND METHOD: The classification into the < 2%, 2-4,9%, 5-9,9%, 10-19,9%, 20-39,9%, and >= 40% risk categories observed by the two functions was compared in 3.270 individuals aged 35 to 74 years with no history of ischaemic heart disease or lipid-lowering drug treatment, recruited in two population samples representative of Girona between 1994 and 2001. The number of lipid-lowering treatment candidates was estimated applying the most recent guidelines for clinical practice, according to the risk level obtained with both functions. RESULTS: The proportion of patients excluded owing to the fact that they already were on lipid-lowering treatment was 6.2%. The Framingham-REGICOR assigned 54.2% of women and 67.9% of men to a lower level of risk as compared to the Framingham-Wilson function. In 0.2% of women and 21.2% of men the decrease was two categories of risk. The figures in diabetic participants were 75.7 and 18.5%, respectively. When the European recommendations published in 2003 were applied, lipid-lowering treatment would have been indicated in 14.5% and in 4.4% of non-diabetic participants by the Framingham-Wilson and the Framingham-REGICOR, respectively. CONCLUSIONS: The calibrated Framingham-REGICOR function assigns a lower coronary risk category in more than 50% of women and almost 90% of men than the uncalibrated Framingham function. The calibrated function is more suitable for risk estimation in primary prevention than the original function in Spain.
BACKGROUND AND OBJECTIVE: The therapeutic consequences of using the Framingham function calibrated by the REGICOR and Framingham investigators (Framingham-REGICOR) in the Spanish population are unknown. The objective of this study was to determine the differences in the classification of the population coronary risk when using the classical Framingham function (Framingham-Wilson) and that calibrated, and its consequences on the theoretical indication of lipid-lowering treatment. PATIENTS AND METHOD: The classification into the < 2%, 2-4,9%, 5-9,9%, 10-19,9%, 20-39,9%, and >= 40% risk categories observed by the two functions was compared in 3.270 individuals aged 35 to 74 years with no history of ischaemic heart disease or lipid-lowering drug treatment, recruited in two population samples representative of Girona between 1994 and 2001. The number of lipid-lowering treatment candidates was estimated applying the most recent guidelines for clinical practice, according to the risk level obtained with both functions. RESULTS: The proportion of patients excluded owing to the fact that they already were on lipid-lowering treatment was 6.2%. The Framingham-REGICOR assigned 54.2% of women and 67.9% of men to a lower level of risk as compared to the Framingham-Wilson function. In 0.2% of women and 21.2% of men the decrease was two categories of risk. The figures in diabeticparticipants were 75.7 and 18.5%, respectively. When the European recommendations published in 2003 were applied, lipid-lowering treatment would have been indicated in 14.5% and in 4.4% of non-diabeticparticipants by the Framingham-Wilson and the Framingham-REGICOR, respectively. CONCLUSIONS: The calibrated Framingham-REGICOR function assigns a lower coronary risk category in more than 50% of women and almost 90% of men than the uncalibrated Framingham function. The calibrated function is more suitable for risk estimation in primary prevention than the original function in Spain.
Authors: Francisco Buitrago; Juan Ignacio Calvo-Hueros; Lourdes Cañón-Barroso; Gerónimo Pozuelos-Estrada; Luis Molina-Martínez; Manuel Espigares-Arroyo; Juan Antonio Galán-González; Francisco J Lillo-Bravo Journal: Ann Fam Med Date: 2011 Sep-Oct Impact factor: 5.166
Authors: Jaume Marrugat; Isaac Subirana; Eva Comín; Carmen Cabezas; Joan Vila; Roberto Elosua; Byung-Ho Nam; Rafel Ramos; Joan Sala; Pascual Solanas; Ferran Cordón; Joan Gené-Badia; Ralph B D'Agostino Journal: J Epidemiol Community Health Date: 2007-01 Impact factor: 3.710
Authors: Manuel A Gómez-Marcos; Gonzalo Grandes; José A Iglesias-Valiente; Alvaro Sánchez; Imanol Montoya; Luis García-Ortiz Journal: Int J Environ Res Public Health Date: 2009-11-11 Impact factor: 3.390
Authors: Maria Rubio-Valera; Antoni Serrano-Blanco; Ignacio Aznar-Lou; Edurne Zabaleta-Del-Olmo; Marc Casajuana-Closas; Alba Sánchez-Viñas; Elizabeth Parody-Rúa; Bonaventura Bolíbar; Montserrat Iracheta-Todó; Oana Bulilete; Tomàs López-Jiménez; Haizea Pombo-Ramos; María Victoria Martín Miguel; Rosa Magallón-Botaya; Jose Ángel Maderuelo-Fernández; Emma Motrico; Juan Bellón; Ruth Martí-Lluch Journal: Int J Behav Nutr Phys Act Date: 2021-07-02 Impact factor: 6.457
Authors: Manuel A Gómez-Marcos; Carlos Martínez-Salgado; Carlos Martin-Cantera; José I Recio-Rodríguez; Yolanda Castaño-Sánchez; Maria Giné-Garriga; Emiliano Rodriguez-Sanchez; Luis García-Ortiz Journal: BMC Cardiovasc Disord Date: 2009-05-11 Impact factor: 2.298
Authors: Carmen Gómez-Vaquero; Alfonso Corrales; Andrea Zacarías; Javier Rueda-Gotor; Ricardo Blanco; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay Journal: Arthritis Res Ther Date: 2013-08-21 Impact factor: 5.156
Authors: Edurne Zabaleta-Del-Olmo; Haizea Pombo; Mariona Pons-Vigués; Marc Casajuana-Closas; Enriqueta Pujol-Ribera; Tomás López-Jiménez; Carmen Cabezas-Peña; Carme Martín-Borràs; Antoni Serrano-Blanco; Maria Rubio-Valera; Joan Llobera; Alfonso Leiva; Caterina Vicens; Clara Vidal; Manuel Campiñez; Remedios Martín-Álvarez; José-Ángel Maderuelo; José-Ignacio Recio; Luis García-Ortiz; Emma Motrico; Juan-Ángel Bellón; Patricia Moreno-Peral; Carlos Martín-Cantera; Ana Clavería; Susana Aldecoa-Landesa; Rosa Magallón-Botaya; Bonaventura Bolíbar Journal: BMC Public Health Date: 2018-07-13 Impact factor: 3.295